Nurix Therapeutics (NRIX) Consolidated Net Income: 2019-2025
Historic Consolidated Net Income for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$86.4 million.
- Nurix Therapeutics' Consolidated Net Income fell 76.53% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.8 million, marking a year-over-year decrease of 38.32%. This contributed to the annual value of -$193.6 million for FY2024, which is 34.47% down from last year.
- Nurix Therapeutics' Consolidated Net Income amounted to -$86.4 million in Q3 2025, which was down 98.83% from -$43.5 million recorded in Q2 2025.
- In the past 5 years, Nurix Therapeutics' Consolidated Net Income ranged from a high of -$24.3 million in Q1 2021 and a low of -$86.4 million during Q3 2025.
- Over the past 3 years, Nurix Therapeutics' median Consolidated Net Income value was -$43.5 million (recorded in 2025), while the average stood at -$47.6 million.
- As far as peak fluctuations go, Nurix Therapeutics' Consolidated Net Income plummeted by 448.05% in 2021, and later surged by 46.53% in 2023.
- Nurix Therapeutics' Consolidated Net Income (Quarterly) stood at -$37.7 million in 2021, then decreased by 23.95% to -$46.7 million in 2022, then increased by 10.19% to -$42.0 million in 2023, then plummeted by 39.55% to -$58.5 million in 2024, then crashed by 76.53% to -$86.4 million in 2025.
- Its Consolidated Net Income stands at -$86.4 million for Q3 2025, versus -$43.5 million for Q2 2025 and -$56.4 million for Q1 2025.